Exec Chat: PacBio Addresses Latest Results, New Tech And Long-Read Sequencing’s Future
Executive Summary
PacBio has been burning through investors’ cash as it works to make long-read sequencing more accessible. Neil Ward, the company’s general manager, laid out his thoughts on the technology, its place in the market and how genomics data can be both effectively and fairly utilized.
You may also be interested in...
PacBio Unveils TRGT, A Tool For Characterizing Rare Disease
PacBio's TRGT can sequence broader sections of DNA, giving scientists and clinicians better odds of spotting repeated sections of DNA linked to disease.
Minute Insight: Cordis-MedAlliance Deal Formalized, Less Than One Year After Announcement
The $1.1bn acquisition of drug-eluting balloon developer MedAlliance will help Cordis return to its roots as an innovative leader in interventional cardiology.
Holocare Hopes To Bring New Dimensions To Surgical Planning
The company has developed a method to convert DICOM images into 3D holograms that can be projected onto VR headsets. Medtech Insight caught up with CEO Alison Sundset to find out how Holocare is paving the way for a more integrated, collaborative form of pre-surgical planning.